Kynurenic acid metabolism in various types of brain pathology in HIV-1 infected patients

International Journal of Tryptophan Research

Volumn 5, Issue 1, 2013, Pages 49-64

  Baran, H ^a,b   Hainfellner, J A ^b   Kepplinger, B ^a,c  

^a Neuropharmacology Neurorehabilitation and Pain Therapy   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c SeneCcure Neurorehabilitation Center Kittsee   (Austria)

Author keywords

Bronchopneumonia; Dementia; Excitatory amino acid; HIV 1 infection; Kynurenic acid; Kynurenine aminotransferases; Neuroprotection

Indexed keywords

EID: 84877930639     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/IJTR.S10627     Document Type: Article

References (49)

1. Fuchs D, Forsman A, Hagberg L, et al. Immune activation and decreased tryptophan in patients with HIV-1 infection. J Interferon Res. Dec 1990;10(6): 599-603.
2. Fuchs D, Möller AA, Reibnegger G, Stöckle E, Werner ER, Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr. 1990;3(9):873-6.
3. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev. Sep 1993;45(3):309-79.
4. Heyes MP, Brew BJ, Saito K, et al. Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. J Neuroimmunol. Sep 1992;40(1):71-80.
5. Heyes MP, Saito K, Crowley JS, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. Oct 1992;115(Pt 5):1249-73.
6. Giulian D, Vaca K, Noonan CA. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science. Dec 14, 1990;250(4987):1593-6.
7. Magnuson DS, Knudsen BE, Geiger JD, Brownstone RM, Nath A. Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol. Mar 1995; 37(3):373-80.
8. Guillemin GJ, Wang L, Brew BJ. Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflammation. Jul 26, 2005;2:16.
9. Heyes MP, Saito K, Markey SP. Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. Biochem J. May 1, 1992;283(Pt 3): 633-5.
10. Lipton SA. Neuronal injury associated with HIV-1: approaches to treatment. Annu Rev Pharmacol Toxicol. 1998;38:159-77.
11. Baran H, Hainfellner JA, Kepplinger B, Mazal PR, Schmid H, Budka H. Kynurenic acid metabolism in the brain of HIV-1 infected patients. J Neural Transm. 2000;107(10):1127-38.
12. Foster AC, Vezzani A, French ED, Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett. Aug 10, 1984;48(3):273-8.
13. Andiné P, Lehmann A, Ellrén K, et al. The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection. Neurosci Lett. Jul 19, 1988;90(1-2):208-12.
14. Baran H, Jellinger K, Deecke L. Kynurenine metabolism in Alzheimer's disease. J Neural Transm. 1999;106(2):165-81.
15. Kepplinger B, Baran H, Kainz A, Ferraz-Leite H, Newcombe J, Kalina P. Age-related increase of kynurenic acid in human cerebrospinal fluid- IgG and beta2-microglobulin changes. Neurosignals. 2005;14(3):126-35.
16. Baran H, Kepplinger B. Cerebrolysin lowers kynurenic acid formation- an in vitro study. Eur Neuropsychopharmacol. Mar 2009;19(3):161-8. Epub Nov 12, 2008.
17. Pocivavsek A, Wu HQ, Potter MC, Elmer GI, Pellicciari R, Schwarcz R. Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology. Oct 2011;36(11):2357-67. doi: 10.1038/npp.2011.127. Epub Jul 27, 2011.
18. Alkondon M, Pereira EF, Eisenberg HM, Kajii Y, Schwarcz R, Albuquerque EX. Age dependency of inhibition of alpha7 nicotinic receptors and tonically active N-methyl-D-aspartate receptors by endogenously produced kynurenic acid in the brain. J Pharmacol Exp Ther. Jun 2011;337(3): 572-582. Epub Jan 26, 2011.
19. Budka H, Costanzi G, Cristina S, etal. Brain pathology induced by infection with the human immunodeficiency virus (HIV). A histological, immunocytochemical, and electron microscopical study of 100 autopsy cases. Acta Neuropathol. 1987;75(2):185-98.
20. Budka H. Neuropathology of human immunodeficiency virus infection. Brain Pathol. Apr 1991;1(3):163-75.
21. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a west African city. AIDS. Dec 1993;7(12): 1569-79.
22. Baran H, Kepplinger B, Heinfelner JA, Lubec G, Budka H. Kynurenic acid metabolism in different types of brain pathology in HIV-1 infected patients. Eur J Neurology. 2002;9(Suppl 2):16, Sc 115.
23. Turski WA, Nakamura M, Todd WP, Carpenter BK, Whetsell WO Jr, Schwarcz R. Identification and quantification of kynurenic acid in human brain tissue. Brain Res. Jun 28, 1988;454(1-2):164-9.
24. Nakamura M, Kawai J, Minatogawa Y, Kido R. The Metabolic Degradation of Kynurenine At Tissue Level by Rat. In: Bender DA, Josef MH, Kochen W, Steinhart H, editors. Progress in tryptophan and serotonin research 1986. De Gruyter W&Co, Berlin-New York. Printed in Germany. pp 55-8.
25. Swartz KJ, Matson WR, MacGarvey U, Ryan EA, Beal MF. Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection. Anal Biochem. Mar 1990;185(2): 363-76.
26. Chiarugi A, Carpenedo R, Molina MT, Mattoli L, Pellicciari R, Moroni F. Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J Neurochem. Sep 1995;65(3):1176-83.
27. Mason M. The kynurenine transaminase of rat kidney. J Biol Chem. Dec 1954;211(2):839-44.
28. Okuno E, Nakamura M, Schwarcz R. Two kynurenine aminotransferases in human brain. Brain Res. Mar 1, 1991;542(2):307-12.
29. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. May 7, 1976;72:248-54.
30. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. Jun 1991;56(6):2007-17.
31. Guillemin GJ, Kerr SJ, Pemberton LA, etal. IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment. J Interferon Cytokine Res. Dec 2001; 21(12):1097-101.
32. Speciale C, Wu HQ, Gramsbergen JB, Turski WA, Ungerstedt U, Schwarcz R. Determination of extracellular kynurenic acid in the striatum of unanesthetized rats: effect of aminooxyacetic acid. Neurosci Lett. Aug 14, 1990;116(1-2):198-203.
33. Jellinger K. The neuropathological diagnosis of Alzheimer disease. J Neural Transm Suppl. 1998;53:97-118.
34. Ketzler S, Weis S, Haug H, Budka H. Loss of neurons in the frontal cortex in AIDS brains. Acta Neuropathol. 1990;80(1):92-4.
35. Gordin FM, Roediger MP, Girard PM, etal. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med. Sep 15, 2008;178(6):630-6. Epub Jul 10, 2008.
36. Kerr-Pontes LR, Oliveira FA, Freire CA. Tuberculosis associated with AIDS: the situation in a Northeastern region of Brazil. Rev Saude Publica. Aug 1997;31(4):323-9.
37. Baran H, Draxler M, Kepplinger B, et al. Kynurenine metabolism in piglet brain due to EMCV infection. Pharmacology. 2003;69:212-7:1.
38. Holtze M, Asp L, Schwieler L, Engberg G, Karlsson H. Induction of the kynurenine pathway by neurotropic influenza A virus infection. J Neurosci Res. Dec 2008;86(16):3674-83.
39. Baran H, Staniek K, Kepplinger B, Stur I, Draxler M, Nohl H. Kynurenines and the respiratory parameters in rat heart mitochondria. Life Sci. 2003; 72(10):1103-15.
40. Baran H, Kepplinger B, Herrera-Marschitz M, Stolze K, Lubec G, Nohl H. Increased kynurenic acid in the brain after neonatal asphyxia. Life Sci. Aug 3, 2001;69(11):1249-56.
41. Baran H, Cairns N, Lubec B, Lubec G. Increased kynurenic acid levels and decreased brain kynurenine aminotransferase I in patients with Down syndrome. Life Sci. 1996;58(21):1891-9.
42. Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol Behav. Sep 10, 2007;92(1-2): 203-9. Epub May 21, 2007.
43. Stone TW. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog Neurobiol. Jun 2001;64(2):185-218.
44. Carlson BA. Rapidly progressive dementia caused by nonenhancing primary lymphoma of the central nervous system. AJNR Am J Neuroradiol. Oct 1996;17(9):1695-7.
45. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. Mar 27, 2003;348(13):1215-22.
46. Davies NW, Guillemin G, Brew BJ. Tryptophan, Neurodegeneration and HIV-associated neurodegenerative disorder. Int J Tryptophan Res. 2010;3: 121-40.
47. Ren J, Sietsma D, Qiu S, Moessler H, Finklestein SP. Cerebrolysin enhances functional recovery following focal cerebral infarction in rats. Restor Neurol Neurosci. 2007;25(1):25-31.
48. Xiao S, Yan H, Yao P; the Cerebrolysin Study Group. The efficacy of cerebrolysin in patients with vascular dementia: results of a chinese multicentre, randomized, double-blind, placebo-controlled trial. Hong Kong J Psychiatry. 1999;9(2):13-9.
49. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. Mar 12, 1997;277(10):813-7.